Xeris Biopharma Holdings, Inc. XERS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenue, net by Product | ||||||
| Gvoke | $20.8M-0.2% | $24.65M+5.9% | $25.15M+9.6% | $23.47M+17.1% | $20.85M+25.7% | |
| Keveyis | $11.89M+4.0% | $12.8M+15.1% | $11.94M-2.1% | $11.49M-12.5% | $11.43M-12.7% | |
| Recorlev | $49.77M+94.9% | $45.33M+100% | $36.98M+109% | $31.44M+136% | $25.53M+141% | |
| Royalty, contract and other revenue | $673K-71.0% | $2.38M-23.3% | $317K-77.5% | $3.83M+147% | $2.32M+518% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Xeris Biopharma Holdings, Inc. break its business down?
- Xeris Biopharma Holdings, Inc. (XERS) reports product revenue, net by product across 4 parts — Gvoke, Keveyis, Recorlev and Royalty, contract and other revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Xeris Biopharma Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Xeris Biopharma Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
